190 related articles for article (PubMed ID: 18502340)
1. Early clinical studies of novel therapies for thyroid cancers.
Sherman SI
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):511-24, xi. PubMed ID: 18502340
[TBL] [Abstract][Full Text] [Related]
2. Novel molecular targeted therapies for refractory thyroid cancer.
Perez CA; Santos ES; Arango BA; Raez LE; Cohen EE
Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors and the thyroid.
Sherman SI
Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23(6):713-22. PubMed ID: 19942148
[TBL] [Abstract][Full Text] [Related]
4. Targeted molecular therapies in thyroid carcinoma.
Romagnoli S; Moretti S; Voce P; Puxeddu E
Arq Bras Endocrinol Metabol; 2009 Dec; 53(9):1061-73. PubMed ID: 20126863
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Covell LL; Ganti AK
Target Oncol; 2015 Sep; 10(3):311-24. PubMed ID: 26335853
[TBL] [Abstract][Full Text] [Related]
6. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Petrelli A; Giordano S
Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
[TBL] [Abstract][Full Text] [Related]
7. [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Török S; Cserepes T M; Rényi-Vámos F; Döme B
Magy Onkol; 2012 Sep; 56(3):199-208. PubMed ID: 23008829
[TBL] [Abstract][Full Text] [Related]
8. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Italiano A; Bui B
Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
[TBL] [Abstract][Full Text] [Related]
9. [Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Wang ZY
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):641-5. PubMed ID: 20021856
[No Abstract] [Full Text] [Related]
10. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
11. [Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Döme B; Magyar M
Magy Onkol; 2008 Sep; 52(3):247-59. PubMed ID: 18845495
[TBL] [Abstract][Full Text] [Related]
12. [New therapeutic options for advanced thyroid cancer].
Willhauck MJ; Schott M; Kreissl MC; Fassnacht M; Spitzweg C
Dtsch Med Wochenschr; 2011 Jun; 136(22):1165-8. PubMed ID: 21611920
[No Abstract] [Full Text] [Related]
13. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
14. [Focus on GIST management].
Tardieu M; Dômont J; Cioffi A; Bonvalot S; Le Cesne A
Bull Cancer; 2010 Jun; 97(6):723-31. PubMed ID: 20483709
[TBL] [Abstract][Full Text] [Related]
15. [KIT and KIT: from biology to clinical use].
Curtit E; Mansi L; Viel E; Dobi E; Chaigneau L; Nguyen T; Pivot X; Blay JY; Kalbacher E
Bull Cancer; 2012 Feb; 99(2):191-7. PubMed ID: 21669561
[TBL] [Abstract][Full Text] [Related]
16. Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
Takami HE
Endocr J; 2011; 58(3):151-3. PubMed ID: 21383525
[TBL] [Abstract][Full Text] [Related]
17. Current and future management of GIST.
Blanke C
Clin Adv Hematol Oncol; 2006 Aug; 4(8):582-3. PubMed ID: 17099615
[No Abstract] [Full Text] [Related]
18. Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S
Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
[TBL] [Abstract][Full Text] [Related]
19. New treatment approaches in metastatic renal cell carcinoma.
Mancuso A; Sternberg CN
Curr Opin Urol; 2006 Sep; 16(5):337-41. PubMed ID: 16905978
[TBL] [Abstract][Full Text] [Related]
20. Novel drugs for renal cell carcinoma.
Vakkalanka BK; Bukowski RM
Expert Opin Investig Drugs; 2008 Oct; 17(10):1501-16. PubMed ID: 18808310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
